OECD Home › Directorate for Science, Technology and Innovation › Biotechnology policies › Latest Documents
This report describes the scientific, industrial, regulatory, and health care management system context in which biomarkers are being developed. It identifies some of the barriers which may impede biomarker research, discovery, development, commercialisation and, ultimately, uptake in clinics.
This book examines international drivers, enabling technologies fast-tracking industrial biotechnology, industry trends, some products appearing on the market, industry structure and finance, and policy measures and trends. It examines separately biofuels, biobased chemicals and bioplastics.
English, , 768kb
This report discusses ways in which both the public and private sectors are seeking to evolve from an “own and protect” model of intellectual property into an era of “own and share”, where value accrues not just to the initial owner of IP, but also to larger society as a whole.
The Recommendation seeks to assist both OECD member and non-member countries in the development of appropriate sustainability assessment methodologies for bio-based products.
Nowhere is innovation more relevant than in the context than human health. Thus, the recent economic worries have done much to bring the issues set out in this document even further up the political agenda.
This book examines the potential economic impacts of nanotechnology, how companies are using nanotechnology for innovation, and what the key challenges in its commercialisation might be.
This biotechnology global forum, "Delivering Global Promise Through the Life Sciences" underlined how the latest social science research into genomics science can help inform key global economic and policy decisions.
As a follow up to the Outlook on Industrial Biotechnology Workshop organised in January 2010, a workshop entitled “Building an Efficient Bio-Based Economy through Industrial Biotechnology” was held in St Petersburg.
For many of today’s new biomedical innovations, the distinctions between different forms of medical products such as drugs, diagnostics and devices no longer apply. Biomedicine also tends to realize its potential today through process innovation, even more than product innovation.
This report is on how to support governments and industry in building a sustainable bio-based economy. The OECD Task Force on Industrial Biotechnology is considering the development of a set of recommendations in the area of Environmental and Economic Sustainability.